Theravance Biopharma/$TBPH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Theravance Biopharma
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Ticker
$TBPH
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
97
ISIN
KYG8807B1068
Website
TBPH Metrics
BasicAdvanced
$458M
-
-$1.19
-0.10
-
Price and volume
Market cap
$458M
Beta
-0.1
52-week high
$10.90
52-week low
$7.44
Average daily volume
271K
Financial strength
Current ratio
4.77
Quick ratio
4.641
Long term debt to equity
22.502
Total debt to equity
22.502
Interest coverage (TTM)
-17.84%
Management effectiveness
Return on assets (TTM)
-7.98%
Return on equity (TTM)
-31.46%
Valuation
Price to revenue (TTM)
6.906
Price to book
2.76
Price to tangible book (TTM)
2.76
Price to free cash flow (TTM)
13.96
Growth
Revenue change (TTM)
6.11%
Earnings per share change (TTM)
36.75%
3-year revenue growth (CAGR)
6.36%
3-year earnings per share growth (CAGR)
-16.32%
What the Analysts think about TBPH
Analyst ratings (Buy, Hold, Sell) for Theravance Biopharma stock.
TBPH Financial Performance
Revenues and expenses
TBPH Earnings Performance
Company profitability
TBPH News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Theravance Biopharma stock?
Theravance Biopharma (TBPH) has a market cap of $458M as of June 02, 2025.
What is the P/E ratio for Theravance Biopharma stock?
The price to earnings (P/E) ratio for Theravance Biopharma (TBPH) stock is 0 as of June 02, 2025.
Does Theravance Biopharma stock pay dividends?
No, Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders as of June 02, 2025.
When is the next Theravance Biopharma dividend payment date?
Theravance Biopharma (TBPH) stock does not pay dividends to its shareholders.
What is the beta indicator for Theravance Biopharma?
Theravance Biopharma (TBPH) has a beta rating of -0.1. This means that it has an inverse relation to market volatility.